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See related research by Zampieri et al., http://ccforum.com/content/19/1/150We applaud the extensive systematic review and meta-
analysis by Zampieri and colleagues on inhaled antibi-
otics for ventilator-associated pneumonia (VAP) [1] but
would like to add some comments regarding inhaled
colistin for treatment of VAP caused by multidrug-
resistant Gram-negative bacteria (MDR-GNB).
In patients with cystic fibrosis, the equivalent of 160
mg colistimethate sodium (CMS) produced high and
therapeutic endobronchial concentrations [2]. However,
to be effective in VAP caused by MDR-GNB, colistin
must attain pulmonary concentrations that substantially
exceed minimal plasma inhibitory levels for these micro-
organisms. Colistin aerosols used in the predominantly
retrospective and observational studies summarized by
Zampieri and colleagues contained CMS doses ranging
from 80 to 300 mg [1]. These doses may be insufficient
to grant any significant or additional therapeutic value
to inhaled colistin, especially when used together with
intravenous antibiotics. Indeed, a total daily inhaled dose
of 240 mg CMS was found to be inadequate to treat
lung infection caused by MDR-GNB [3]. A recent review
recommended inhalation of 160 mg CMS every 8 h for
severe pulmonary infections [4]. Finally, a daily dose of
1,200 mg inhaled CMS used in monotherapy or associ-
ated with a 3-day course of intravenous aminoglycosides
cured VAP caused by MDR-GNB as effectively as VAP
caused by β-lactam susceptible GNB [5]. In contrast
with intravenous administration, high doses of nebulized
colistin are not associated with an increased risk of kid-
ney injury, even when given for a prolonged period of
time [5].* Correspondence: Patrick.Honore@uzbrussel.be
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creativecommons.org/publicdomain/zero/1.0/We strongly salute aerosolized colistin as an important
alternative or adjunct therapy to treat VAP caused by
MDR-GNB, provided that the daily inhaled dose is suffi-
ciently high.
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